**Supplementary table 2. Number of ADA-positive patients at weeks 12, 24, and 52**

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment group | Week 12 | Week 24 | Week 52 |
| LBEC0101 | 1/187 (0.5%) | 1/187 (0.5%) | 1/187 (0.5%) |
| ETN-RP | 8/187 (4.3%) | 4/187 (2.1%) | 7/187 (3.7%) |

*All (3/3) of the ADA-positive patients in the LBEC0101 group and 94.4% (17/18) of the ADA-positive patients in the ETN-RP group had ADAs at one of the three (weeks 12, 24, and 52) assessments. The remaining one patient in the ETN-RP group had ADAs at weeks 12 and 24.*